2.44
전일 마감가:
$2.34
열려 있는:
$2.36
하루 거래량:
681.72K
Relative Volume:
0.49
시가총액:
$313.97M
수익:
$514.70M
순이익/손실:
$2.72M
주가수익비율:
-15.36
EPS:
-0.1589
순현금흐름:
$17.08M
1주 성능:
+2.52%
1개월 성능:
-1.61%
6개월 성능:
-57.71%
1년 성능:
-25.38%
Organogenesis Holdings Inc Stock (ORGO) Company Profile
명칭
Organogenesis Holdings Inc
전화
781-575-0775
주소
85 DAN ROAD, CANTON, MA
Compare ORGO vs TAK, HLN, TEVA, ZTS, UTHR
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
|
ORGO
Organogenesis Holdings Inc
|
2.44 | 313.97M | 514.70M | 2.72M | 17.08M | -0.1589 |
|
TAK
Takeda Pharmaceutical Co Adr
|
15.63 | 49.39B | 29.91B | 1.30B | 3.49B | 0.4056 |
|
HLN
Haleon Plc Adr
|
8.96 | 39.55B | 14.54B | 2.22B | 2.58B | 0.4871 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
31.48 | 36.66B | 17.53B | 1.58B | 444.18M | 1.3457 |
|
ZTS
Zoetis Inc
|
78.71 | 33.00B | 9.51B | 2.64B | 2.14B | 6.0361 |
|
UTHR
United Therapeutics Corp
|
536.59 | 22.78B | 3.17B | 1.29B | 1.01B | 27.09 |
Organogenesis Holdings Inc Stock (ORGO) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-06-28 | 개시 | Lake Street | Buy |
| 2024-02-07 | 개시 | Cantor Fitzgerald | Overweight |
| 2023-06-15 | 개시 | Morgan Stanley | Equal-Weight |
| 2023-05-24 | 업그레이드 | BTIG Research | Neutral → Buy |
| 2022-11-10 | 다운그레이드 | BTIG Research | Buy → Neutral |
| 2022-08-10 | 다운그레이드 | Oppenheimer | Outperform → Perform |
| 2020-01-10 | 개시 | SVB Leerink | Outperform |
| 2019-08-26 | 재개 | Credit Suisse | Outperform |
| 2019-05-02 | 개시 | Credit Suisse | Outperform |
| 2019-04-17 | 개시 | Oppenheimer | Outperform |
| 2019-04-11 | 개시 | SunTrust | Buy |
모두보기
Organogenesis Holdings Inc 주식(ORGO)의 최신 뉴스
Spotlight On 3 Promising Penny Stocks With At Least $200M Market Cap - simplywall.st
Organogenesis Holdings Inc (ORGO) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Organogenesis Holdings Inc (ORGO) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Organogenesis Holdings Inc (ORGO) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Organogenesis Holdings Inc - TradingKey
Organogenesis Holdings Inc (ORGO) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Organogenesis Holdings Inc (ORGO) Institutional Confidence - TradingKey
Organogenesis Holdings Inc (ORGO) Valuation: PE, PB & Fair Value Analysis - TradingKey
Organogenesis re-elects Garrett Lustig to its board - TradingView
Organogenesis (NASDAQ: ORGO) investors reelect full board and approve pay - Stock Titan
The Quiet Revolution in Regenerative Medicine: From Replacing Tissue to Rebuilding It - GlobeNewswire
Organogenesis: Mesmerized By Wound Care Struggles, Upcoming ReNu Blockbuster Overlooked - Seeking Alpha
Organogenesis Holdings Inc (ORGO) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
ORGO Q1 2026 Earnings: Significant EPS Miss Highlights Persistent ChallengesEPS Guidance Update - newsline.com
ORGO Q1 2026 Earnings: EPS Misses Estimates by 29.66% as Losses WidenNegative Surprise Momentum - newsline.com
Organogenesis Holdings (ORGO) Consolidates Near Support After Marginal DeclineVolatility Skew - newsline.com
The Body as Blueprint - lifehealth.com
Organogenesis plans rolling BLA submission for ReNu by year-end - Investing.com
The Body as Blueprint: A Recently Public Biotech Bets That Regrown Tissue Beats Replacement Parts - PR Newswire
Number of shareholders of Organogenesis Holdings, Inc. Class A – DUS:2PQ - TradingView
Organogenesis shares jump 20% following positive clinical trial results - MSN
Organogenesis Holdings Faces Selling Pressure as ORGO Slips to $2.57Oversold Bounce Ideas - newsline.com
Organogenesis Holdings (ORGO) Declines 1.5% as Stock Tests Key Support ZoneFund Manager Survey - The Legal Advocate
Truist initiates Organogenesis stock at Hold on reimbursement shifts - Investing.com UK
Truist initiates Organogenesis stock at Hold on reimbursement shifts By Investing.com - Investing.com India
Truist Initiates Organogenesis Holdings at Hold With $3 Price Target - marketscreener.com
ORGO stock rallies after hours on clearing regulatory pathway for pain relief treatment - MSN
- The Legal Advocate
Organogenesis Holdings (ORGO) Edges Lower as Stock Hovers Near Key SupportBullish Percent Index - The Legal Advocate
Organogenesis rises as PuraPlyAM succeeds in diabetic foot ulcers - MSN
Organogenesis Holdings (ORGO) Holds Steady at $2.66 – Consolidation Phase in PlayALMA Signal - The Legal Advocate
ORGO Q1 2026 Earnings: EPS Falls Short of Estimates Amid Operational ChallengesEPS Miss Report - newsline.com
ORGO Q1 2026 Earnings: Significant EPS Miss Raises ConcernsSlow Growth Warning - newsline.com
Organogenesis Holdings stock (US68620V1026): BTIG rating cut puts focus on outlook after Q1 update - AD HOC NEWS
Is Organogenesis Holdings Inc. (ORGO) Losing Momentum? BTIG Pulls Buy Rating After Q1 Update - Insider Monkey
Organogenesis outlines 2025 revenue guidance of $500M–$525M as CMS policy shift drives growth outlook - MSN
Organogenesis Holdings (ORGO) Q1 2026 Earnings Miss by Significant: Key TakeawaysQuarterly Profit Report - newsline.com
Organogenesis Holdings stock (US68620V1026): FDA warning letter and Nasdaq notice put focus on compl - AD HOC NEWS
Organogenesis Holdings stock (US68620V1026): shares react to earnings and outlook update - AD HOC NEWS
Organogenesis Holdings Inc.Class A (NQ: ORGO - FinancialContent
Organogenesis Holdings stock (US68620V1026): Q1 earnings miss on revenue and EPS - AD HOC NEWS
TradingKey - TradingKey
Organogenesis Holdings Inc. (NASDAQ:ORGO) Q1 2026 Earnings Call Transcript - Insider Monkey
RI skin-maker Organogenesis reports steep Q1 loss amid CMS policy change - The Business Journals
Organogenesis (ORGO) Q1 2026 Earnings Transcript - AOL.com
Organogenesis Holdings Inc (ORGO) 재무 분석
매출
순이익
현금흐름
주당 순 이익
자본화:
|
볼륨(24시간):